Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Stomach Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-squamous Non-small-cell Lung Cancer 1

Interventions

Brentuximab Vedotin 3relmacabtagene autoleucel 2fludarabine phosphate 2fludarabine 2Cytarabine 2Bortezomib 2Antilymphocyte Serum 2xihuang 1tocilizumab 1tislelizumab 1sofosbuvir-velpatasvir drug combination 1sintilimab 1rasburicase 1ledipasvir 1entecavir 1apatinib 1aflibercept 1acalabrutinib 1Urate Oxidase 1Trabectedin 1Thiotepa 1Thalidomide 1Tenofovir 1Tamsulosin 1Sofosbuvir 1Sevoflurane 1Rivaroxaban 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recurrence × apatinib × Clear all
NCT03376958 2019-07-25

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Zhengzhou University

Phase 4 Completed
32 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡